Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis (Q50892830)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 January 2016

Language	Label	Description	Also known as
English	Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis	scientific article published on 12 January 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

author name string

M C Cheung

1

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

A Prica

2

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

J Graczyk

3

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

R Buckstein

4

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

K K W Chan

5

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

publication date

12 January 2016

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

57

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

8

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

1865-1875

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Optimal therapy of advanced Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Evolution of radiation therapy within the German Hodgkin Study Group trials

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Evaluation of direct medical costs of hospitalization for febrile neutropenia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Pulmonary outcomes in survivors of childhood cancer: a systematic review

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Burden of illness in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

A guide to cost-effectiveness acceptability curves.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

ABVD chemotherapy in the treatment of Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Strategic approach to the management of Hodgkin’s disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK)

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Cost effectiveness of treatment options in advanced breast cancer in the UK.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Treatment costs in Hodgkin's disease: a cost-utility analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

The trajectory of palliative care costs over the last 5 months of life: a Canadian longitudinal study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1117609

21 January 2018

Identifiers

10.3109/10428194.2015.1117609

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26758765

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50892830&oldid=2262721720"